Investegate |Indivior PLC Announcements | Indivior PLC: Indivior Raises FY 2021 Guidance investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
5 - Adjusted (Adj.) basis excludes the impact of exceptional items as referenced in Notes 3 and 4. Comment by Mark Crossley, CEO of Indivior PLC We have seen an encouraging start in FY 2021 with growth in net revenue, operating profit and cash from execution against our strategic priorities. Despite the ongoing impacts of COVID-19, SUBLOCADE® (buprenorphine extended-release) injection achieved solid net revenue growth both on a sequential and year-over-year basis, and we expanded our Organized Health Systems (OHS) platform to build the foundation for future growth. Looking ahead, we are seeing healthcare restrictions in the US begin to ease from the rapid pace of COVID-19 vaccinations, which supports our expectation of increased in-person interactions with healthcare practitioners in the second half of the year. As such, we are reiterating our FY 2021 base case guidance.